20+ hour, 21+ min ago  (261+ words) The ESR1-mutated metastatic breast cancer market is projected to grow rapidly at a 9. 6% CAGR from 2026 to 2036, driven by rising cases of endocrine-resistant HR-positive/HER2-negative breast cancer and advances in precision oncology. Novel therapies like Giredestrant, Camizestrant, and VEPPANU, the first…...